Oncodesign

Oncodesign is an international leader in the preclinical evaluation of anticancer therapies and stands out in the industry on the following points : Innovation: Oncodesign devises new solutions (Pharmimage®, CReMEC, IMAkinib®, Nanocyclix®, etc.) that bring relevant rational, economic and competitive answers to therapeutic and biomarker development. Science: Oncodesign boasts extensive know-how, rigor, and rationality, as exemplified through our synopses (custom-tailored drug program designs). Technology: With its experimental models and state-of-the-art imaging for diagnostics, drug evaluation and monitoring, Oncodesign enjoys strong recognition as a technology company with unique integrated platforms. Dynamism: Oncodesign's dynamic team stands out for its vitality, solidarity and capacity to develop solutions that anticipate customers' needs in order to offer rapid and effective responses. Oncodesign holds a unique place in the industry and enjoys a strong image of quality.
Type
Public
HQ
Dijon, FR
Founded
1995
Employees
103 (est)
Oncodesign was founded in 1995 and is headquartered in Dijon, FR

Key People at Oncodesign

Philippe Genne

Philippe Genne

President and CEO

Oncodesign Locations

Dijon, FR

Oncodesign Metrics

Oncodesign Summary

Market capitalization

€101 M

Closing share price

€14.8
Oncodesign's latest market capitalization is €101 M.

Oncodesign Market Value History

Oncodesign Company Life